Target Information

Target General Infomation
Target ID
T84726
Target Name
Rho associated protein kinase
Target Type
Clinical Trial
Disease Asthma [ICD10: J45]
Glaucoma [ICD9: 365; ICD10: H40-H42]
Solid tumours [ICD9: 140-199, 210-229; ICD10: C00-D48]
Spinal cord injury [ICD10: S14, S24, S34]
BioChemical Class
Transferases (EC:2)
EC Number
EC 2.7.11.1
Drugs and Mode of Action
Drug(s) Roclatan Drug Info Phase 3 Glaucoma [525325]
AMA-76 Drug Info Phase 2 Glaucoma [524752]
AR-12286 Drug Info Phase 2 Glaucoma [524084]
Rhopressa Drug Info Phase 2 Glaucoma [533091]
Cethrin Drug Info Phase 1/2 Spinal cord injury [536648]
Y-39983 Drug Info Phase 1/2 Glaucoma [522584]
AT13148 Drug Info Phase 1 Solid tumours [523886]
Y-27632 Drug Info Terminated Asthma [540753], [546846]
Modulator AMA-76 Drug Info [532649]
AR-12286 Drug Info [531577]
AT13148 Drug Info
Cethrin Drug Info [531381]
Rhopressa Drug Info [533091]
Roclatan Drug Info [1572591]
Y-27632 Drug Info
Y-39983 Drug Info
References
Ref 522584ClinicalTrials.gov (NCT00846989) Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension. U.S. National Institutes of Health.
Ref 523886ClinicalTrials.gov (NCT01585701) Phase I Study of AT13148, a Novel AGC Kinase Inhibitor. U.S. National Institutes of Health.
Ref 524084ClinicalTrials.gov (NCT01699464) A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months. U.S. National Institutes of Health.
Ref 524752ClinicalTrials.gov (NCT02136940) Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension. U.S. National Institutes of Health.
Ref 525325ClinicalTrials.gov (NCT02558400) Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension.
Ref 533091Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4.
Ref 536648Emerging drugs for spinal cord injury. Expert Opin Emerg Drugs. 2008 Mar;13(1):63-80.
Ref 540753(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5290).
Ref 546846Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010598)
Ref
Ref 531381A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J Neurotrauma. 2011 May;28(5):787-96.
Ref 531577Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol. 2011 Nov;152(5):834-41.e1.
Ref 532649AMA0076, a novel, locally acting Rho kinase inhibitor, potently lowers intraocular pressure in New Zealand white rabbits with minimal hyperemia. Invest Ophthalmol Vis Sci. 2014 Feb 18;55(2):1006-16.
Ref 533091Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4.
Ref 1572591Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.